Free Trial
NASDAQ:CTOR

Citius Oncology 2/14/2025 Earnings Report

Citius Oncology logo
$1.72 +0.05 (+2.99%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$1.72 +0.01 (+0.29%)
As of 10/24/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Citius Oncology EPS Results

Actual EPS
-$0.09
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Citius Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Citius Oncology Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Citius Oncology Earnings Headlines

Citius Oncology Prepares LYMPHIR Launch for Q4 2025
U.S. Government Sparking Crypto Rally
Missed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underway. Our new blueprint shows how early altcoin investors are positioning now, just like they did before the last wave of gains.tc pixel
See More Citius Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Citius Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Citius Oncology and other key companies, straight to your email.

About Citius Oncology

Citius Oncology (NASDAQ:CTOR) is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

View Citius Oncology Profile

More Earnings Resources from MarketBeat